Subcutaneous interferon beta-1a in COVID-19: raking the ashes of an intervention trial

Abstract

There is increasing evidence that the current COVID-19 pandemic will continue to affect global health and economic prosperity for months and possibly years to come. Initial successes in vaccine development and roll-out in several territories have not translated into effective global vaccine coverage, with protection as low as 2% in many countries.1 Furthermore, recent data from studies in early vaccine recipients suggest fading protective immunity. New variants of concern are also emerging, which are less likely to be covered by current vaccines.